Apathy and depression in amnestic and non-amnestic mild cognitive impairment

Alfonsina D'Iorio1, Gabriella Santangelo1

  • 1Department of Psychology, University of Campania Luigi Vanvitelli, Caserta, Italy.

Abstract

Insights

Mild cognitive impairment (MCI) subtypes, amnestic MCI (aMCI) and non-amnestic MCI (naMCI), exhibit distinct behavioral profiles. Depression is more common in aMCI, but functional autonomy is similar across both groups.

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychiatry

Background:

  • Neuropsychiatric symptoms in mild cognitive impairment (MCI) subtypes are not well-defined.
  • It remains unclear if amnestic MCI (aMCI) and non-amnestic MCI (naMCI) differ in behavioral patterns and daily living (ADL) decline.

Purpose of the Study:

  • To delineate the behavioral and functional profiles of aMCI and naMCI subgroups.
  • To investigate the association between apathy, depression, and functional autonomy in MCI patients.

Main Methods:

  • Sixty-eight MCI patients were evaluated using neuropsychological tests.
  • Participants were classified as aMCI (n=37) or naMCI (n=31).
  • Apathy, depression, and functional autonomy were assessed via questionnaires.

Main Results:

  • aMCI patients exhibited more severe depressive symptoms than naMCI patients.
  • No significant differences in apathy scores were observed between the two MCI subtypes.
  • Both aMCI and naMCI groups demonstrated comparable functional autonomy.

Conclusions:

  • The distinction between amnestic and non-amnestic MCI is clinically relevant due to differing cognitive and behavioral profiles.
  • Tailored treatment strategies may be necessary for each MCI subtype.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
132
Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
204
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
226
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
215
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270